Arthur D. Riggs, the diabetes expert who developed the technology that led to the first human synthetic insulin for the treatment of diabetes, died March 23 at age 82 after battling cancer. A biotechnology pioneer and a longtime leader at City of Hope, Riggs served as director emeritus of Beckman Research Institute of City of Hope... […]
City of Hope has evaluated Curate Biosciences’ Cell Processing System for advanced cell separation and plans to integrate the platform into its workflow to manufacture investigational CAR T-cell immunotherapy, the company said.
A COVID-19 investigational vaccine, developed by City of Hope scientists and now licensed to GeoVax Labs Inc., produced a robust neutralizing antibody and T cell response against SARS-CoV-2 with no significant side effects in a phase I clinical trial led by John Zaia, Aaron D. Miller and Edith Miller Chair for Gene Therapy.
City of Hope’s Department of Stem Cell Biology and Regenerative Medicine received a $4.9 million grant from the California Institute for Regenerative Medicine to train scientists in basic stem cell research and its clinical translation.
Vince Jensen was named chief clinical operating officer of City of Hope. Jensen will lead clinical operations on City of Hope’s main campus in Los Angeles and throughout its network of more than 35 care locations in Southern California.
City of Hope has completed its previously announced acquisition of Cancer Treatment Centers of America (The Cancer Letter, Jan. 21, 2022).
The acquisition of Cancer Treatment Centers of America will allow City of Hope to build a national network of cancer centers that is fundamentally different from those of other cancer centers.
City of Hope has entered a definitive agreement to acquire Cancer Treatment Centers of America, a network of oncology hospitals and outpatient care centers across the United States (The Cancer Letter, May 7, 2021).
